Validation Data Gallery
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Product Information
60135-2-PBS targets Chromogranin A as part of a matched antibody pair:
MP50241-2: 60135-2-PBS capture and 60135-3-PBS detection (validated in Cytometric bead array)
MP50241-3: 68851-1-PBS capture and 60135-2-PBS detection (validated in Cytometric bead array)
Unconjugated mouse monoclonal antibody pair in PBS only (BSA and azide free) storage buffer at a concentration of 1 mg/mL, ready for conjugation.
This conjugation ready format makes antibodies ideal for use in many applications including: ELISAs, multiplex assays requiring matched pairs, mass cytometry, and multiplex imaging applications.Antibody use should be optimized by the end user for each application and assay.
| Tested Reactivity | human, mouse, rat, pig |
| Host / Isotype | Mouse / IgG1 |
| Class | Monoclonal |
| Type | Antibody |
| Immunogen | Chromogranin A fusion protein Ag0807 相同性解析による交差性が予測される生物種 |
| Full Name | chromogranin A (parathyroid secretory protein 1) |
| Calculated molecular weight | 51 kDa |
| Observed molecular weight | 50 kDa |
| GenBank accession number | BC006459 |
| Gene Symbol | Chromogranin A |
| Gene ID (NCBI) | 1113 |
| RRID | AB_2918358 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | P10645 |
| Storage Buffer | PBS Only |
| Storage Conditions | Store at -80°C. |
Background Information
Chromogranin A is a member of the granin family of neuroendocrine secretory proteins. It is located in secretory vesicles of neurons and endocrine cells. Chromogranin A is the precursor to several functional peptides including vasostatin, pancreastatin, catestatin and parastatin. These peptides negatively modulate the neuroendocrine function of the releasing cell (autocrine) or nearby cells (paracrine). CgA is one of the most used tumor markers in NET's (neuroendocrine tumors) , and elevated CgA concentrations have been demonstrated in serum or plasma of patients with different types of these tumors.